GLP-1 Receptor Agonists in Pulmonary Hypertension: Mechanistic Rationale, Preclinical Evidence, and Clinical Knowledge Gaps
Authors:
- 16 September 2026
- journal article
- review article
- Published by Springer Nature in Lung
- Vol. 204 (1) , 68
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- EXPLORING THE POTENTIAL BENEFITS OF GLP-1 RECEPTOR AGONISTS IN PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM A LARGE DATABASE STUDYChest, 2025
- Pulmonary Artery Pressure Trajectories in Heart Failure Patients Treated with GLP-1 Receptor AgonistsESC Heart Failure, 2025
- The gut microbiota regulates hypothalamic inflammation and leptin sensitivity in Western diet-fed mice via a GLP-1R-dependent mechanismCell Reports, 2021
- Corrigendum to “Meta-Analysis Comparing Outcomes of Therapies for Patients with Central Sleep Apnea and Heart Failure With Reduced Ejection Fraction”The American Journal of Cardiology, 2020
- Glucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulationBiochemical Pharmacology, 2016
- Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitusDiabetologia, 2013
- Mortality and the self‐controlled case series method: Letter to the EditorPharmacoepidemiology and Drug Safety, 2012
- Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetesDiabetologia, 2012
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialDiabetologia, 2009
- Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequencesFEBS Letters, 1995